| Immune checkpoint inhibitor (ICI)-related hepatotoxicity remains one of the management challenges in current oncologic therapy. Approximately one-third of patients with grade 3 or higher liver toxicity show inadequate response to first-line corticosteroid treatment and require secondary immunosuppressive agents. This study systematically reviewed literature from database including PubMed up to July 2026, identifying 78 patients with refractory ICI-induced hepatotoxicity treated with secondary immunosuppressants. The pooled analysis revealed that mycophenolate mofetil (MMF) was the most commonly used agent (54/78, 69.2%), achieving a biochemical normalization rate of 80.9% in evaluable cases. Tocilizumab monotherapy (n=8) had a normalization rate of 50.0%, but with a shorter median time to normalization (21 days vs. 62 days). Combination therapies (MMF plus tocilizumab or tacrolimus) led to normalization in all 9 evaluable cases. Infliximab is not recommended as a standard second-line option due to its potential hepatotoxicity, according to major guidelines. Current evidence is primarily retrospective, and there remains insufficient prospective data on the optimal timing, dosage, and duration of secondary immunosuppressive therapy. |